{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:03:16Z","timestamp":1791237796537,"version":"4.1.0"},"reference-count":131,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T00:00:00Z","timestamp":1654905600000},"content-version":"vor","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"NIA","doi-asserted-by":"publisher","award":["R21AG059176"],"award-info":[{"award-number":["R21AG059176"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"NIA","doi-asserted-by":"publisher","award":["RF1AG05148501"],"award-info":[{"award-number":["RF1AG05148501"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.medj.2021.05.001","type":"journal-article","created":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T20:13:29Z","timestamp":1623788009000},"page":"666-681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Turning enemies into allies\u2014reprogramming tumor-associated macrophages for cancer therapy"],"prefix":"10.1016","volume":"2","author":[{"given":"Martina","family":"Molgora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5222-4987","authenticated-orcid":false,"given":"Marco","family":"Colonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2021.05.001_bib1","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.medj.2021.05.001_bib2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/19420862.2015.1011450","article-title":"Macrophages are critical effectors of antibody therapies for cancer","volume":"7","author":"Weiskopf","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.medj.2021.05.001_bib3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1084\/jem.20151570","article-title":"Immunometabolism governs dendritic cell and macrophage function","volume":"213","author":"O\u2019Neill","year":"2016","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.medj.2021.05.001_bib4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","article-title":"Macrophage activation and polarization: nomenclature and experimental guidelines","volume":"41","author":"Murray","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2021.05.001_bib5","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nrd.2018.169","article-title":"Targeting macrophages: therapeutic approaches in cancer","volume":"17","author":"Cassetta","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.medj.2021.05.001_bib6","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1126\/science.6828888","article-title":"Regulation of the macrophage content of neoplasms by chemoattractants","volume":"220","author":"Bottazzi","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.medj.2021.05.001_bib7","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13059-017-1362-4","article-title":"Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment","volume":"18","author":"M\u00fcller","year":"2017","journal-title":"Genome Biol."},{"key":"10.1016\/j.medj.2021.05.001_bib8","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.1252510","article-title":"The cellular and molecular origin of tumor-associated macrophages","volume":"344","author":"Franklin","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.medj.2021.05.001_bib9","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature10138","article-title":"CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis","volume":"475","author":"Qian","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.medj.2021.05.001_bib10","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1084\/jem.20180534","article-title":"Macrophages of distinct origins contribute to tumor development in the lung","volume":"215","author":"Loyher","year":"2018","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.medj.2021.05.001_bib11","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.immuni.2017.08.018","article-title":"Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression","volume":"47","author":"Zhu","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2021.05.001_bib12","doi-asserted-by":"crossref","first-page":"108571","DOI":"10.1016\/j.celrep.2020.108571","article-title":"Distinct populations of immune-suppressive macrophages differentiate from monocytic myeloid-derived suppressor cells in cancer","volume":"33","author":"Kwak","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.medj.2021.05.001_bib13","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.cell.2020.08.040","article-title":"Onco-fetal reprogramming of endothelial cells drives immunosuppressive macrophages in hepatocellular carcinoma","volume":"183","author":"Sharma","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.medj.2021.05.001_bib14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/imr.12215","article-title":"Origin, development, and homeostasis of tissue-resident macrophages","volume":"262","author":"Haldar","year":"2014","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.medj.2021.05.001_bib15","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.medj.2021.05.001_bib16","doi-asserted-by":"crossref","first-page":"30576","DOI":"10.18632\/oncotarget.15736","article-title":"Prognostic significance of tumor-associated macrophages in breast cancer: a meta-analysis of the literature","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.medj.2021.05.001_bib17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/08941939.2019.1631411","article-title":"Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in hepatocellular carcinoma","volume":"34","author":"Zhang","year":"2021","journal-title":"J.\u00a0Invest. Surg."},{"key":"10.1016\/j.medj.2021.05.001_bib18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ygyno.2017.07.007","article-title":"Prognostic significance of tumor-associated macrophages in ovarian cancer: a meta-analysis","volume":"147","author":"Yuan","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.medj.2021.05.001_bib19","doi-asserted-by":"crossref","first-page":"e0170042","DOI":"10.1371\/journal.pone.0170042","article-title":"The prognostic and clinicopathological significance of tumor-associated macrophages in patients with gastric cancer: a meta-analysis","volume":"12","author":"Yin","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.medj.2021.05.001_bib20","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s00384-020-03686-9","article-title":"The prognostic and clinicopathological value of tumor-associated macrophages in patients with colorectal cancer: a systematic review and meta-analysis","volume":"35","author":"Yang","year":"2020","journal-title":"Int. J. Colorectal Dis."},{"key":"10.1016\/j.medj.2021.05.001_bib21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nature13862","article-title":"Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis","volume":"515","author":"Bonapace","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.medj.2021.05.001_bib22","doi-asserted-by":"crossref","first-page":"9417","DOI":"10.1158\/0008-5472.CAN-07-1286","article-title":"Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in\u00a0vivo","volume":"67","author":"Loberg","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2021.05.001_bib23","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8274.CD-10-0028","article-title":"Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy","volume":"1","author":"DeNardo","year":"2011","journal-title":"Cancer Discov."},{"key":"10.1016\/j.medj.2021.05.001_bib24","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.3337","article-title":"CSF-1R inhibition alters macrophage polarization and blocks glioma progression","volume":"19","author":"Pyonteck","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2021.05.001_bib25","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1158\/2326-6066.CIR-19-0152","article-title":"Trabectedin reveals a strategy of immunomodulation in chronic lymphocytic leukemia","volume":"7","author":"Banerjee","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.medj.2021.05.001_bib26","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/febs.14277","article-title":"A drug development perspective on targeting tumor-associated myeloid cells","volume":"285","author":"Majety","year":"2018","journal-title":"FEBS J."},{"key":"10.1016\/j.medj.2021.05.001_bib27","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.cell.2017.07.023","article-title":"TREM2 maintains microglial metabolic fitness in Alzheimer\u2019s disease","volume":"170","author":"Ulland","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.medj.2021.05.001_bib28","doi-asserted-by":"crossref","first-page":"ra38","DOI":"10.1126\/scisignal.2000500","article-title":"TREM2- and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1","volume":"3","author":"Peng","year":"2010","journal-title":"Sci. Signal."},{"key":"10.1016\/j.medj.2021.05.001_bib29","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.4049\/jimmunol.1102836","article-title":"TREM2 and \u03b2-catenin regulate bone homeostasis by controlling the rate of osteoclastogenesis","volume":"188","author":"Otero","year":"2012","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.medj.2021.05.001_bib30","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41582-018-0072-1","article-title":"TREM2 - a key player in microglial biology and Alzheimer disease","volume":"14","author":"Ulland","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.medj.2021.05.001_bib31","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.cell.2019.05.054","article-title":"Lipid-associated macrophages control metabolic homeostasis in a Trem2-dependent manner","volume":"178","author":"Jaitin","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.medj.2021.05.001_bib32","doi-asserted-by":"crossref","first-page":"108626","DOI":"10.1016\/j.celrep.2020.108626","article-title":"Dynamic shifts in the composition of resident and recruited macrophages influence tissue remodeling in NASH","volume":"34","author":"Daemen","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.medj.2021.05.001_bib33","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41586-019-1631-3","article-title":"Resolving the fibrotic niche of human liver cirrhosis at single-cell level","volume":"575","author":"Ramachandran","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.medj.2021.05.001_bib34","doi-asserted-by":"crossref","first-page":"135197","DOI":"10.1172\/JCI135197","article-title":"TREM2 sustains macrophage-hepatocyte metabolic coordination in nonalcoholic fatty liver disease and sepsis","volume":"131","author":"Hou","year":"2021","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.medj.2021.05.001_bib35","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1161\/CIRCRESAHA.117.312509","article-title":"Single-cell RNA-seq reveals the transcriptional landscape and heterogeneity of aortic macrophages in murine atherosclerosis","volume":"122","author":"Cochain","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/j.medj.2021.05.001_bib36","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1002\/cam4.2113","article-title":"Dissecting intratumoral myeloid cell plasticity by single cell RNA-seq","volume":"8","author":"Song","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.medj.2021.05.001_bib37","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.cell.2017.04.014","article-title":"Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses","volume":"169","author":"Lavin","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.medj.2021.05.001_bib38","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.cell.2020.06.032","article-title":"Coupled scRNA-seq and intracellular protein activity reveal an immunosuppressive role of TREM2 in cancer","volume":"182","author":"Katzenelenbogen","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.medj.2021.05.001_bib39","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.cell.2020.07.013","article-title":"TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy","volume":"182","author":"Molgora","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.medj.2021.05.001_bib40","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/ijc.31545","article-title":"Expression of scavenger receptor MARCO defines a targetable tumor-associated macrophage subset in non-small cell lung cancer","volume":"143","author":"La Fleur","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.medj.2021.05.001_bib41","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1286-4579(00)00296-3","article-title":"The macrophage receptor MARCO","volume":"2","author":"Kraal","year":"2000","journal-title":"Microbes Infect."},{"key":"10.1016\/j.medj.2021.05.001_bib42","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/j.celrep.2016.04.084","article-title":"Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis","volume":"15","author":"Georgoudaki","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.medj.2021.05.001_bib43","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/imm.12042","article-title":"Sialoadhesin - a macrophage-restricted marker of immunoregulation and inflammation","volume":"138","author":"O\u2019Neill","year":"2013","journal-title":"Immunology"},{"key":"10.1016\/j.medj.2021.05.001_bib44","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ccell.2019.02.009","article-title":"Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets","volume":"35","author":"Cassetta","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.medj.2021.05.001_bib45","doi-asserted-by":"crossref","first-page":"106012","DOI":"10.1016\/j.intimp.2019.106012","article-title":"Breast cancer cells promote CD169+ macrophage-associated immunosuppression through JAK2-mediated PD-L1 upregulation on macrophages","volume":"78","author":"Jing","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.medj.2021.05.001_bib46","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11302-020-09701-6","article-title":"Regulation of tumor infiltrated innate immune cells by adenosine","volume":"16","author":"Strakhova","year":"2020","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.medj.2021.05.001_bib47","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s10753-013-9621-3","article-title":"The adenosine-dependent angiogenic switch of macrophages to an M2-like phenotype is independent of interleukin-4 receptor alpha (IL-4R\u03b1) signaling","volume":"36","author":"Ferrante","year":"2013","journal-title":"Inflammation"},{"key":"10.1016\/j.medj.2021.05.001_bib48","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.4049\/jimmunol.162.6.3607","article-title":"IFN-gamma up-regulates the A2B adenosine receptor expression in macrophages: a mechanism of macrophage deactivation","volume":"162","author":"Xaus","year":"1999","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.medj.2021.05.001_bib49","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.4049\/jimmunol.157.10.4634","article-title":"Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice","volume":"157","author":"Hask\u00f3","year":"1996","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.medj.2021.05.001_bib50","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.4049\/jimmunol.1001567","article-title":"A2B adenosine receptor blockade enhances macrophage-mediated bacterial phagocytosis and improves polymicrobial sepsis survival in mice","volume":"186","author":"Belikoff","year":"2011","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.medj.2021.05.001_bib51","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.celrep.2019.04.091","article-title":"Blocking antibodies targeting the CD39\/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies","volume":"27","author":"Perrot","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.medj.2021.05.001_bib52","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s00262-020-02569-w","article-title":"Blockade of CD73 delays glioblastoma growth by modulating the immune environment","volume":"69","author":"Azambuja","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.medj.2021.05.001_bib53","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.molmed.2013.03.005","article-title":"CD39 and CD73 in immunity and inflammation","volume":"19","author":"Antonioli","year":"2013","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.medj.2021.05.001_bib54","doi-asserted-by":"crossref","first-page":"a008748","DOI":"10.1101\/cshperspect.a008748","article-title":"Clearing the dead: apoptotic cell sensing, recognition, engulfment, and digestion","volume":"5","author":"Hochreiter-Hufford","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.medj.2021.05.001_bib55","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","article-title":"Role of CD47 as a marker of self on red blood cells","volume":"288","author":"Oldenborg","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.medj.2021.05.001_bib56","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev-immunol-032713-120142","article-title":"The interaction between signal regulatory protein alpha (SIRP\u03b1) and CD47: structure, function, and therapeutic target","volume":"32","author":"Barclay","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.medj.2021.05.001_bib57","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1158\/0008-5472.CAN-03-1708","article-title":"CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A","volume":"64","author":"Manna","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2021.05.001_bib58","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000132568","article-title":"Association of CD47 with natural killer cell-mediated cytotoxicity of head-and-neck squamous cell carcinoma lines","volume":"29","author":"Kim","year":"2008","journal-title":"Tumour Biol."},{"key":"10.1016\/j.medj.2021.05.001_bib59","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.medj.2021.05.001_bib60","doi-asserted-by":"crossref","first-page":"14016","DOI":"10.1073\/pnas.0906549106","article-title":"Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells","volume":"106","author":"Chan","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.medj.2021.05.001_bib61","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.medj.2021.05.001_bib62","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.medj.2021.05.001_bib63","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.canlet.2015.02.036","article-title":"Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma","volume":"360","author":"Xiao","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.medj.2021.05.001_bib64","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1073\/pnas.1121623109","article-title":"The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors","volume":"109","author":"Willingham","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.medj.2021.05.001_bib65","doi-asserted-by":"crossref","first-page":"101221","DOI":"10.1016\/j.beha.2020.101221","article-title":"The promise of macrophage directed checkpoint inhibitors in myeloid malignancies","volume":"33","author":"Swoboda","year":"2020","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.medj.2021.05.001_bib66","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1200\/JCO.18.02018","article-title":"First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers","volume":"37","author":"Sikic","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2021.05.001_bib67","article-title":"Macrophage targeting in cancer","author":"Lopez-Yrigoyen","year":"2020","journal-title":"Ann. N Y Acad. Sci."},{"key":"10.1016\/j.medj.2021.05.001_bib68","doi-asserted-by":"crossref","first-page":"E168","DOI":"10.21037\/jtd.2017.02.30","article-title":"Targeting CD47: the achievements and concerns of current studies on cancer immunotherapy","volume":"9","author":"Huang","year":"2017","journal-title":"J.\u00a0Thorac. Dis."},{"key":"10.1016\/j.medj.2021.05.001_bib69","doi-asserted-by":"crossref","first-page":"18342","DOI":"10.1073\/pnas.1106550108","article-title":"CD47-signal regulatory protein-\u03b1 (SIRP\u03b1) interactions form a barrier for antibody-mediated tumor cell destruction","volume":"108","author":"Zhao","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.medj.2021.05.001_bib70","doi-asserted-by":"crossref","first-page":"39021","DOI":"10.18632\/oncotarget.16547","article-title":"CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.medj.2021.05.001_bib71","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1158\/1078-0432.CCR-18-0652","article-title":"Anti-folate receptor alpha-directed antibody therapies restrict the growth of triple-negative breast cancer","volume":"24","author":"Cheung","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2021.05.001_bib72","doi-asserted-by":"crossref","first-page":"e89140","DOI":"10.1172\/jci.insight.89140","article-title":"Anti-SIRP\u03b1 antibodies as a potential new tool for cancer immunotherapy","volume":"2","author":"Yanagita","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.medj.2021.05.001_bib73","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nature22076","article-title":"SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin","volume":"544","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.medj.2021.05.001_bib74","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.4049\/jimmunol.1900562","article-title":"Structural and functional basis for LILRB immune checkpoint receptor recognition of HLA-G isoforms","volume":"203","author":"Kuroki","year":"2019","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.medj.2021.05.001_bib75","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/ni961","article-title":"Crystal structure of HLA-A2 bound to LIR-1, a host and viral major histocompatibility complex receptor","volume":"4","author":"Willcox","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2021.05.001_bib76","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1084\/jem.186.11.1809","article-title":"A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells","volume":"186","author":"Colonna","year":"1997","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.medj.2021.05.001_bib77","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0171-2985(00)80050-9","article-title":"The ILT family of leukocyte receptors","volume":"202","author":"Allan","year":"2000","journal-title":"Immunobiology"},{"key":"10.1016\/j.medj.2021.05.001_bib78","first-page":"161","article-title":"ILT receptors at the interface between lymphoid and myeloid cells","volume":"251","author":"Cella","year":"2000","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.medj.2021.05.001_bib79","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41590-017-0004-z","article-title":"Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy","volume":"19","author":"Barkal","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2021.05.001_bib80","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.1172\/JCI97570","article-title":"Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity","volume":"128","author":"Chen","year":"2018","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.medj.2021.05.001_bib81","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2567.2005.02177.x","article-title":"Paired immunoglobulin-like receptors and their MHC class I recognition","volume":"115","author":"Takai","year":"2005","journal-title":"Immunology"},{"key":"10.1016\/j.medj.2021.05.001_bib82","doi-asserted-by":"crossref","first-page":"5261","DOI":"10.1073\/pnas.94.10.5261","article-title":"A novel pair of immunoglobulin-like receptors expressed by B cells and myeloid cells","volume":"94","author":"Kubagawa","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.medj.2021.05.001_bib83","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.immuni.2011.02.004","article-title":"Paired immunoglobin-like receptor-B regulates the suppressive function and fate of myeloid-derived suppressor cells","volume":"34","author":"Ma","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2021.05.001_bib84","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nri2056","article-title":"Siglecs and their roles in the immune system","volume":"7","author":"Crocker","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.medj.2021.05.001_bib85","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cell.2013.01.011","article-title":"Induction of Siglec-G by RNA viruses inhibits the innate immune response by promoting RIG-I degradation","volume":"152","author":"Chen","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.medj.2021.05.001_bib86","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nbt.1846","article-title":"Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction","volume":"29","author":"Chen","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.medj.2021.05.001_bib87","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1126\/science.1168988","article-title":"CD24 and Siglec-10 selectively repress tissue damage-induced immune responses","volume":"323","author":"Chen","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.medj.2021.05.001_bib88","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1182\/blood-2013-12-545335","article-title":"Siglec-G-CD24 axis controls the severity of graft-versus-host disease in mice","volume":"123","author":"Toubai","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.medj.2021.05.001_bib89","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","article-title":"CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy","volume":"572","author":"Barkal","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.medj.2021.05.001_bib90","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1146\/annurev-immunol-032414-112049","article-title":"Coinhibitory pathways in immunotherapy for cancer","volume":"34","author":"Baumeister","year":"2016","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.medj.2021.05.001_bib91","doi-asserted-by":"crossref","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.medj.2021.05.001_bib92","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","article-title":"Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab","volume":"5","author":"Topalian","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.medj.2021.05.001_bib93","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.medj.2021.05.001_bib94","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1002\/cam4.1518","article-title":"Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases","volume":"7","author":"Dhupkar","year":"2018","journal-title":"Cancer Med."},{"key":"10.1016\/j.medj.2021.05.001_bib95","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1158\/2326-6066.CIR-17-0537","article-title":"Programmed cell death ligand 1 (PD-L1) signaling regulates macrophage proliferation and activation","volume":"6","author":"Hartley","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.medj.2021.05.001_bib96","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.cell.2018.09.030","article-title":"High-dimensional analysis delineates myeloid and lymphoid compartment remodeling during successful immune-checkpoint cancer therapy","volume":"175","author":"Gubin","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.medj.2021.05.001_bib97","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.4049\/jimmunol.1601515","article-title":"Akt signaling pathway in macrophage activation and M1\/M2 polarization","volume":"198","author":"Vergadi","year":"2017","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.medj.2021.05.001_bib98","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ccr.2011.04.016","article-title":"Receptor tyrosine kinases and TLR\/IL1Rs unexpectedly activate myeloid cell PI3k\u03b3, a single convergent point promoting tumor inflammation and progression","volume":"19","author":"Schmid","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.medj.2021.05.001_bib99","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3K\u03b3 is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.medj.2021.05.001_bib100","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1541-7786.MCR-13-0682","article-title":"A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1\u03b1 and HIF2\u03b1 stability and tumor growth, angiogenesis, and metastasis","volume":"12","author":"Joshi","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.medj.2021.05.001_bib101","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1158\/2159-8290.CD-15-0827","article-title":"Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer","volume":"6","author":"Gunderson","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.medj.2021.05.001_bib102","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nrd4154","article-title":"Histone lysine demethylases as targets for anticancer therapy","volume":"12","author":"H\u00f8jfeldt","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.medj.2021.05.001_bib103","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nature21409","article-title":"Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages","volume":"543","author":"Guerriero","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.medj.2021.05.001_bib104","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nchembio.1223","article-title":"Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group","volume":"9","author":"Lobera","year":"2013","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.medj.2021.05.001_bib105","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41586-020-2054-x","article-title":"Epigenetic therapy inhibits metastases by disrupting premetastatic niches","volume":"579","author":"Lu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.medj.2021.05.001_bib106","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrc2809","article-title":"Eicosanoids and cancer","volume":"10","author":"Wang","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.medj.2021.05.001_bib107","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","article-title":"Cyclooxygenase-dependent tumor growth through evasion of immunity","volume":"162","author":"Zelenay","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.medj.2021.05.001_bib108","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.immuni.2020.10.020","article-title":"Antagonistic inflammatory phenotypes dictate tumor fate and response to immune checkpoint blockade","volume":"53","author":"Bonavita","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2021.05.001_bib109","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1158\/0008-5472.CAN-06-4174","article-title":"Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells","volume":"67","author":"Sinha","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2021.05.001_bib110","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1158\/0008-5472.CAN-19-2843","article-title":"Tumor-derived prostaglandin E2 promotes p50 NF-\u03baB-dependent differentiation of monocytic MDSCs","volume":"80","author":"Porta","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2021.05.001_bib111","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1158\/0008-5472.CAN-10-3055","article-title":"COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells","volume":"71","author":"Fujita","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2021.05.001_bib112","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-15-1032","article-title":"IFN\u03b3 and CCL2 cooperate to redirect tumor-infiltrating monocytes to degrade fibrosis and enhance chemotherapy efficacy in pancreatic carcinoma","volume":"6","author":"Long","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.medj.2021.05.001_bib113","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1126\/science.1198443","article-title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.medj.2021.05.001_bib114","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/annonc\/mdx049","article-title":"A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study","volume":"28","author":"Monk","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.medj.2021.05.001_bib115","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1158\/1078-0432.CCR-16-1934","article-title":"Phase Ib Trial of the Toll-like receptor 8 agonist, motolimod (VTX-2337), combined with cetuximab in patients with recurrent or metastatic SCCHN","volume":"23","author":"Chow","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2021.05.001_bib116","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1158\/2159-8290.CD-18-0280","article-title":"SD-101 in combination with pembrolizumab in advanced melanoma: results of a phase Ib, multicenter study","volume":"8","author":"Ribas","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.medj.2021.05.001_bib117","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1158\/1078-0432.CCR-17-1866","article-title":"Therapeutic immune modulation against solid cancers with intratumoral poly-ICLC: a pilot trial","volume":"24","author":"Kyi","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2021.05.001_bib118","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.intimp.2018.11.019","article-title":"Preclinical development of the TLR9 agonist DV281 as an inhaled aerosolized immunotherapeutic for lung cancer: Pharmacological profile in mice, non-human primates, and human primary cells","volume":"66","author":"Kell","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.medj.2021.05.001_bib119","doi-asserted-by":"crossref","first-page":"6748","DOI":"10.1158\/1078-0432.CCR-12-1149","article-title":"Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer","volume":"18","author":"Adams","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2021.05.001_bib120","doi-asserted-by":"crossref","first-page":"e587","DOI":"10.1016\/j.clgc.2017.10.019","article-title":"Intravesical immunomodulatory imiquimod enhances Bacillus Calmette-Gu\u00e9rin downregulation of nonmuscle-invasive bladder cancer","volume":"16","author":"Camargo","year":"2018","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.medj.2021.05.001_bib121","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41551-018-0236-8","article-title":"TLR7\/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy","volume":"2","author":"Rodell","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.medj.2021.05.001_bib122","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.4049\/jimmunol.1401160","article-title":"Effective innate and adaptive antimelanoma immunity through localized TLR7\/8 activation","volume":"193","author":"Singh","year":"2014","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.medj.2021.05.001_bib123","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1200\/JCO.1996.14.2.343","article-title":"Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy","volume":"14","author":"Pujade-Lauraine","year":"1996","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2021.05.001_bib124","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T\u00a0cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.medj.2021.05.001_bib125","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrd.2017.84","article-title":"CAR T therapies drive into new terrain","volume":"16","author":"Kingwell","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.medj.2021.05.001_bib126","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.medj.2021.05.001_bib127","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/s41416-019-0578-3","article-title":"Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix","volume":"121","author":"Zhang","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.medj.2021.05.001_bib128","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.trecan.2015.11.004","article-title":"Ontogeny of tumor-associated macrophages and its implication in cancer regulation","volume":"2","author":"Franklin","year":"2016","journal-title":"Trends Cancer"},{"key":"10.1016\/j.medj.2021.05.001_bib129","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.cell.2019.08.009","article-title":"Fate mapping via Ms4a3-expression history traces monocyte-derived cells","volume":"178","author":"Liu","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.medj.2021.05.001_bib130","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/s41590-019-0417-y","article-title":"The macrophage tetraspan MS4A4A enhances dectin-1-dependent NK cell-mediated resistance to metastasis","volume":"20","author":"Mattiola","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2021.05.001_bib131","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/s41591-020-0879-3","article-title":"Common germline variants of the human APOE gene modulate melanoma progression and survival","volume":"26","author":"Ostendorf","year":"2020","journal-title":"Nat. Med."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634021001926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634021001926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:54:36Z","timestamp":1763002476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634021001926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":131,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2666634021001926"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2021.05.001","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Turning enemies into allies\u2014reprogramming tumor-associated macrophages for cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2021.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}